middle.news
Avecho Accelerates Phase III CBD Trial Recruitment Ahead of 2026 Interim Analysis
9:27am on Tuesday 29th of July, 2025 AEST
•
Healthcare
Read Story
Avecho Accelerates Phase III CBD Trial Recruitment Ahead of 2026 Interim Analysis
9:27am on Tuesday 29th of July, 2025 AEST
Key Points
131 patients dosed in Phase III CBD insomnia trial
210 patients target for interim analysis completion in H2 2025
New trial sites in Sydney and Gold Coast boost recruitment
Interim results anticipated in early 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE